Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. reduced its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 77,155 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. Alliancebernstein L.P. owned 0.16% of Theravance Biopharma worth $726,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TBPH. KLP Kapitalforvaltning AS purchased a new position in Theravance Biopharma during the fourth quarter worth $69,000. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma in the fourth quarter valued at about $103,000. SG Americas Securities LLC grew its position in Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,349 shares in the last quarter. XTX Topco Ltd increased its stake in Theravance Biopharma by 34.5% during the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 5,243 shares during the period. Finally, Magnetar Financial LLC boosted its position in Theravance Biopharma by 125.8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 15,328 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $8.62 on Friday. The company has a market cap of $431.01 million, a price-to-earnings ratio of -8.53 and a beta of 0.14. The firm has a fifty day moving average of $9.11 and a 200-day moving average of $9.15. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.33.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.